
The U.S. Food and Drug Administration (FDA) has removed the clinical hold on Finch Therapeutics Group (NASDAQ:FNCH) investigational new drug (IND) application for CP101 in the prevention of recurrent C. difficile infection (CDI).
The regulatory agency lifted the clinical hold following a review of information Finch provided related to its SARS-CoV-2 screening procedures and associated informed consent language.